Clinical Trials Logo
  1. Home
  2. Cytomegalovirus (CMV)
  3. NCT01611974

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

Cytomegalovirus (CMV) Clinical Trial

Official title:
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients

Clinical Trial Summary

This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01611974
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 2
Start date July 17, 2012
Completion date December 5, 2014
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05319353 - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection Phase 3
Completed NCT05571137 - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Not yet recruiting NCT06243731 - A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Not yet recruiting NCT06439342 - A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections Phase 3
Completed NCT05576805 - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
Not yet recruiting NCT06213974 - A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Completed NCT02775240 - Study of SHP620 (Maribavir) in Healthy Adults Phase 1
Completed NCT05137717 - A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection Phase 3
Completed NCT02931539 - Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir Phase 3
Completed NCT02927067 - A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants Phase 3